Novel inhibitors of mammalian tight junction opening
AssigneeAlba Therapeutics Corporation
InventorAmir Tamiz
Life of this patent
Estimating the term…
Abstract
The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.
Claims168
A peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 2-69.
A method of treating an excessive or undesirable permeability of a tissue containing tight junctions comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating inflammatory bowel disease comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating Crohn's disease comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating ulcerative colitis comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating Celiac disease comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating acute respiratory distress syndrome comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating acute lung injury comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating chronic obstructive pulmonary disorder comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating type 1 diabetes comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A method of treating asthma comprising:
- administering to a subject in need thereof a composition comprising a peptide tight junction antagonist, wherein the peptide comprises an amino acid sequence selected from the group of SEQ ID NOs:
- 2-69.
A pharmaceutical composition comprising a peptide that reduces tight junction permeability and a pharmaceutically acceptable carrier and/or excipient, the peptide having from 3 to 5 amino acids.
Dependencies are inferred from the claim text.